Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MedImmune LLC
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed B-cell Chronic Lymphocytic Leukemia (CLL) according to the National Cancer Institute criteria; Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2; Adequate hematological function
You may not be if
Any chemotherapy, radiotherapy, immunotherapy, biologic, investigational, or hormonal therapy for treatment of lymphoma within 28 days prior to treatment;
Exposure to bendamustine within the 180 days before study enrollment
Prior autologous or allogeneic stem cell transplantation (SCT);
Clinically significant abnormality on electrocardiogram (ECG) as determined by the treating physician or medical monitor;
History of other invasive malignancy within 5 years except for localized/in situ carcinomas;
Evidence of active infection, Confirmed current central nervous system involvement by leukemia or lymphoma;
Clareo Health | A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
